The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Development and clinical validation of circulating tumor cell (CTC) biomarkers in clear cell renal cell carcinoma (ccRCC) for the OMNIVORE clinical trial.
 
Waddah Arafat
No Relationships to Disclose
 
Joshua Desotelle
No Relationships to Disclose
 
Tamara Rodems
No Relationships to Disclose
 
Rana R. McKay
No Relationships to Disclose
 
Jason Abel
No Relationships to Disclose
 
Toni K. Choueiri
Honoraria - NCCN; UpToDate
Consulting or Advisory Role - alligent; AstraZeneca; Bayer; Bristol-Myers Squibb; Cerulean Pharma; Eisai; Exelixis; Foundation Medicine; GlaxoSmithKline; Merck; Novartis; Peloton Therapeutics; Pfizer; Prometheus; Roche/Genentech
Research Funding - Agensys (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Celldex (Inst); Exelixis (Inst); GlaxoSmithKline (Inst); Merck (Inst); Novartis (Inst); Peloton Therapeutics (Inst); Pfizer (Inst); Roche/Genentech (Inst); TRACON Pharma (Inst)
Travel, Accommodations, Expenses - advisory boards/consultancy
 
Joshua Michael Lang
Stock and Other Ownership Interests - Salus Discovery
Consulting or Advisory Role - Sanofi; Sanofi
Research Funding - Agensys (Inst); Medivation (Inst); Novartis (Inst)
Patents, Royalties, Other Intellectual Property - I am listed on the patent on a technology for rare cell capture and analysis. This technology has been licensed by Salus Discovery, LLC though no commercial products are available.